Characteristics of patients with or without derivative chromosome 9 deletions
| Clinical characteristics . | Total n = 339 . | Cases without deletions n = 280; 83% . | Cases with deletions n = 59; 17% . | ABL/BCRspanning deletionsn = 21; 6% . | Deletion of ABLonly or BCRonlyn = 38; 11% . |
|---|---|---|---|---|---|
| Age, y (range) | 50 (10-83) | 50 (10-83) | 49 (11-72) | 56 (21-71) | 45 (11-65) |
| Male sex, no. | 58 | 59 | 54 | 52 | 55 |
| Median observation time, y (range) | 7.1 (0.3-16) | 6.9 (0.3-16) | 8.0 (0.5-16) | 5.7 (0.5-9.8) | 8.4 (0.5-16) |
| No. alive (%) | 158 (47) | 125 (45) | 33 (56) | 3 (14) | 30 (79) |
| Median time on IFN, mon (range) | 17 (1-115) | 18 (0.1-115) | 14 (1-106) | 14 (3.8-81) | 13 (0.2-106) |
| Treatment after IFN failure, % | |||||
| Imatinib | 62 (18) | 49 (18) | 13 (22) | 4 (19) | 9 (24) |
| In first chronic phase | 49 (14) | 39 (14) | 10 (17) | 2 (10) | 8 (21) |
| Allogeneic stem cell transplantation | 129 (38) | 109 (39) | 20 (34) | 6 (29) | 14 (37) |
| In first chronic phase | 105 (31) | 87 (31) | 18 (31) | 6 (29) | 12 (32) |
| Sokal risk groups, no. (%) | |||||
| Evaluable | 338 (99) | 279 (99) | 59 (100) | 21 (100) | 38 (100) |
| Low | 133 (39) | 108 (39) | 25 (42) | 10 (48) | 15 (39) |
| Intermediate | 112 (33) | 91 (33) | 21 (36) | 9 (43) | 12 (32) |
| High | 93 (28) | 80 (28) | 13 (22) | 2 (9) | 11 (29) |
| Hasford risk groups, no. (%) | |||||
| Evaluable | 338 (99) | 279 (99) | 59 (100) | 21 (100) | 38 (100) |
| Low | 132 (39) | 106 (38) | 26 (44) | 11 (52) | 15 (39) |
| Intermediate | 166 (49) | 142 (51) | 24 (41) | 10 (48) | 14 (37) |
| High | 40 (12) | 31 (11) | 9 (15) | 0 | 9 (24) |
| Clinical characteristics . | Total n = 339 . | Cases without deletions n = 280; 83% . | Cases with deletions n = 59; 17% . | ABL/BCRspanning deletionsn = 21; 6% . | Deletion of ABLonly or BCRonlyn = 38; 11% . |
|---|---|---|---|---|---|
| Age, y (range) | 50 (10-83) | 50 (10-83) | 49 (11-72) | 56 (21-71) | 45 (11-65) |
| Male sex, no. | 58 | 59 | 54 | 52 | 55 |
| Median observation time, y (range) | 7.1 (0.3-16) | 6.9 (0.3-16) | 8.0 (0.5-16) | 5.7 (0.5-9.8) | 8.4 (0.5-16) |
| No. alive (%) | 158 (47) | 125 (45) | 33 (56) | 3 (14) | 30 (79) |
| Median time on IFN, mon (range) | 17 (1-115) | 18 (0.1-115) | 14 (1-106) | 14 (3.8-81) | 13 (0.2-106) |
| Treatment after IFN failure, % | |||||
| Imatinib | 62 (18) | 49 (18) | 13 (22) | 4 (19) | 9 (24) |
| In first chronic phase | 49 (14) | 39 (14) | 10 (17) | 2 (10) | 8 (21) |
| Allogeneic stem cell transplantation | 129 (38) | 109 (39) | 20 (34) | 6 (29) | 14 (37) |
| In first chronic phase | 105 (31) | 87 (31) | 18 (31) | 6 (29) | 12 (32) |
| Sokal risk groups, no. (%) | |||||
| Evaluable | 338 (99) | 279 (99) | 59 (100) | 21 (100) | 38 (100) |
| Low | 133 (39) | 108 (39) | 25 (42) | 10 (48) | 15 (39) |
| Intermediate | 112 (33) | 91 (33) | 21 (36) | 9 (43) | 12 (32) |
| High | 93 (28) | 80 (28) | 13 (22) | 2 (9) | 11 (29) |
| Hasford risk groups, no. (%) | |||||
| Evaluable | 338 (99) | 279 (99) | 59 (100) | 21 (100) | 38 (100) |
| Low | 132 (39) | 106 (38) | 26 (44) | 11 (52) | 15 (39) |
| Intermediate | 166 (49) | 142 (51) | 24 (41) | 10 (48) | 14 (37) |
| High | 40 (12) | 31 (11) | 9 (15) | 0 | 9 (24) |